Importance of the Keap1-Nrf2 pathway in NSCLC: Is it a possible biomarker?
| Autor: | Raúl Barrera-Rodríguez |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
Oncology medicine.medical_specialty medicine.medical_treatment Review General Biochemistry Genetics and Molecular Biology 03 medical and health sciences Therapeutic approach Internal medicine medicine General Pharmacology Toxicology and Pharmaceutics Lung cancer Chemotherapy Oncogene business.industry General Neuroscience Cancer General Medicine Cell cycle respiratory system medicine.disease Molecular medicine respiratory tract diseases 030104 developmental biology Biomarker (medicine) business |
| Popis: | Worldwide, lung cancer remains the most common cause of cancer-related mortality, with non-small cell lung cancer (NSCLC) accounting for 85% of all diagnosed lung cancer cases. Chemotherapy is considered the standard of care for patients with advanced NSCLC; however, the tumors can develop mechanisms that inactivate these drugs. Comparative genomic analyses have revealed that disruptions in the kelch-like ECH-associated protein 1 (Keap1)-nuclear factor erythroid-2-related factor-2 (Nrf2) pathway are frequent in NSCLC, although Nrf2 mutations occur less frequently than Keap1 mutations. As the Keap1-Nrf2 pathway appears to be a primary regulator of key cellular processes that aid to resist the action of chemotherapy drugs, the clinical implementation of Nrf2 inhibitors in patients with advanced NSCLC may be a useful therapeutic approach for patients harboring KEAP1-NRF2 mutations. The aim of the present review was to highlight findings of how constitutive Nrf2 activation may be a specific biomarker for predicting patients most likely to benefit from classical chemotherapy drugs, overall improving patient survival rate. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|